# Chinese medicine maker addresses global TCM gathering, bringing flagship heart pill to trial in Singapore

- Link: https://www.thailand-business-news.com/pr-news/chinese-medicine-maker-addresses-global-tcm-gathering-bringing-flagship-heart-pill-to-trial-in-singapore
- Published: 2026-10-19T18:40:00+07:00
- Author: Media OutReach

SINGAPORE – [Media OutReach Newswire](https://www.media-outreach.com/) – 19 October
2026 – A leading Chinese medicine maker told a global gathering of traditional Chinese
medicine (TCM) practitioners here Saturday that a 500-year-old tradition built on
treating the whole patient and tailoring treatment has offered an Eastern answer
to aging societies and chronic disease worldwide.

![Wang Lei, chairman of Da Ren Tang and president of Tianjin Pharmaceutical Group,
addresses the congress.](https://images.media-outreach.com/release.php/Thumb/1600x1994/
825449/825449-Wang-Lei-1-jpg-1600x1994.jpeg)

 _Wang Lei, chairman of Da Ren Tang and president of Tianjin Pharmaceutical Group,
addresses the congress._

 According to a press report issued by China News Service (CNS), Tianjin Pharmaceutical
Da Ren Tang Group, one of China’s oldest pharmacy houses, also announced that it
would conduct an international randomized, double-blind, controlled trial of its
flagship heart remedy, sold in English as Suxiao Jiuxin Pills, in collaboration 
with Singapore General Hospital, the city-state’s largest acute tertiary hospital.

 [https://www.youtube.com/watch?v=W0ac_rOwMNM](https://www.youtube.com/watch?v=W0ac_rOwMNM)

 Wang Lei, chairman of Da Ren Tang and president of Tianjin Pharmaceutical Group,
made both points in her address at the opening ceremony of the 23rd World Congress
of Chinese Medicine in Singapore. She noted that Chinese medicine’s holistic approach
and pattern-based diagnosis give it an advantage in strengthening public health 
systems, and that the industry must demonstrate this through internationally recognized,
verifiable evidence, the CNS report said.

 The study marks the first time a Chinese proprietary medicine has undergone clinical
trials at a major Western-medicine hospital in Singapore, the CNS report highlighted.

 “We have always believed that Chinese medicine cannot stop at product exports,”
Wang said, adding that the trial would offer internationally recognized and verifiable
clinical evidence.

 The congress, hosted by the World Federation of Chinese Medicine Societies and 
organized by the Singapore Chinese Physicians’ Association, ran Oct. 16-18 at Raffles
City Convention Centre under the theme “Addressing Global Health Challenges, Integrating
Chinese Medicine into National Health Systems.” About 1,400 experts, officials and
industry representatives from 25 countries and regions participated, the CNS report
added.

 Wang devoted much of her speech, titled “Gathering the Wisdom of Traditional Medicine
to Shoulder the Global Mission of Health,” to arguing that traditional medicine 
belongs in the global public health conversation rather than on its margins.

 Chinese medicine’s emphasis on the body as a whole, and on tailoring treatment 
to individual patients’ symptom patterns, gives it a distinct advantage in strengthening
public health systems, she noted.

 For countries facing aging populations and a rising burden of chronic disease, 
TCM represents “a valuable solution with Eastern characteristics,” Wang said, highlighting
its contribution to China’s “Health Silk Road” vision and its role in China’s broader
approach to global health governance.

 Wang said Da Ren Tang’s roughly 70 years of exporting, dating back to 1955, had
taught the company that a remedy must suit the actual health needs of the people
who take it rather than be shipped abroad merely as a cultural product.

 She set out a three-part plan: concentrate clinical research on cardiovascular 
and cerebrovascular diseases, respiratory conditions, digestive health, musculoskeletal
disorders and skin diseases, working with overseas medical institutions to turn 
traditional experience into evidence regulators can evaluate; follow international
research norms while pursuing product registrations and high-quality studies abroad;
and recognize that medical systems and regulatory cultures differ from country to
country.

 “We have to respect the medical systems and cultural contexts of each country and
build an open, mutually trusting and mutually beneficial form of cooperation,” Wang
was quoted as saying by CNS.

 According to the CNS report, the company is working with Singapore General Hospital
on the study and hopes that solid results will help traditional medicine enter national
health systems and reach more patients overseas.

 Wang called on the congress to bring Chinese medicine standards into alignment 
with international rules, build platforms for sharing research results, and tell
the story of Chinese medicine to the world.

 Da Ren Tang traces its pharmacy lineage to 1522 and has been listed in Singapore
since 1997. The company holds 122 exclusive products and 599 drug approval numbers,
sells more than 150 products in more than 20 countries, and ranks among China’s 
top five exporters of traditional Chinese medicine, according to the CNS report.

Hashtag: #ChinaNewsService

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/494958/36955)

**Source** : [Chinese medicine maker addresses global TCM gathering, bringing flagship heart pill to trial in Singapore](https://www.media-outreach.com/news/singapore/2026/10/19/494958/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://r2.thailand-business-news.com/wp-content/uploads/
2026/10/media-outreach-newswire-2025.svg)
